Dopamine receptor D2 (long isoform) (D2L) (D2L)

The Dopamine receptor D2 (long isoform), commonly known as D2L, is a G protein-coupled receptor (GPCR) and the most prevalent splice variant of the D2 receptor in the central nervous system (UniProt, 2024). It is primarily localized postsynaptically in the striatum and limbic regions, where it couples with Gi/o proteins to inhibit adenylyl cyclase activity and regulate downstream signaling (PubMed, 2021). D2L plays a fundamental role in the modulation of motor control, reward-driven behavior, and cognitive functions (StatPearls, 2023). Clinically, D2L is the primary target for antipsychotic drugs, which act as antagonists or partial agonists to mitigate the positive symptoms of schizophrenia associated with dopaminergic overactivity (NIH, 2023). Additionally, D2L agonists are utilized in the management of Parkinson's disease to compensate for the loss of endogenous dopamine and in the treatment of hyperprolactinemia by inhibiting prolactin release from the pituitary (PubChem, 2024). Therapeutic intervention is often limited by side effects such as extrapyramidal symptoms and tardive dyskinesia, which arise from receptor blockade in the nigrostriatal pathway (Wikipedia, 2024).

Other names

D2L receptorDRD2LDopamine D2 receptor long isoformD2LR

Antagonism, partial agonism, and agonism of the G protein-coupled receptor to modulate dopaminergic signaling pathways.